BCM
RNTX

Bridgeway Capital Management’s Rein Therapeutics RNTX Stock Holding History

Bridgeway Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,680
Closed -$312K – 1474
2018
Q3 		$312K Buy
5,680
+2,500
+79% +$168K ﹤0.01% 1248
2018
Q2 		$345K Buy
+3,180
New +$360K ﹤0.01% 1225

Other funds holding RNTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
JA
JOYN Advisors Atlanta, Georgia $300M AUM 14.91% 1-Year Est. Return

Bridgeway Capital Management's RNTX Position: Q4 2018 in Review

Bridgeway Capital Management sold out of Rein Therapeutics (RNTX) in Q4 2018, closing a stake of 5,680 shares — an estimated $312K sold.

Bridgeway Capital Management first reported a position in RNTX in Q2 2018 and held it in 2 quarters. The position peaked at $345K in Q2 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q4 2018.

  • Bridgeway Capital Management reported no remaining Rein Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Bridgeway Capital Management sold 5,680 Rein Therapeutics shares in Q4 2018, an estimated $312K.
  • Bridgeway Capital Management first reported a position in Rein Therapeutics in Q2 2018 and held it in 2 quarters.
  • Bridgeway Capital Management's Rein Therapeutics position peaked at $345K in Q2 2018.
  • 23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2018.

Based on Bridgeway Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.